The text starts here.

News Release

February 25th, 2005

US FDA Tentative Approval for ANDA Filing of Donepezil Hydrochloride

Eisai Co., Ltd.
Eisai Inc.

U.S. Food & Drug Administration (FDA) announced on their website that FDA has issued a tentative approval for donepezil hydrochloride to Ranbaxy Laboratories Ltd. Donepezil is Eisai's branded medicine Aricept(R) .

The tentative approval by FDA does not authorize Ranbaxy Laboratories Ltd. to sell and market donepezil hydrochloride before the expiry of the Eisai's product patent. Eisai s donepezil will be protected at least until its product patent expiry in November 2010. The tentative approval will not be effective before November 2010.

Corporate Communications DepartmentCathy Pollini
Eisai Co., Ltd. Corporate Public Relations
81-3-3817-5120Eisai Inc.